Barbara Yosaitis, MD
Internal Medicine · Fairfax, VANPI 1679617997
Payments from drug & device makers
Across 383 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- Pfizer$950
- Amgen$669
- Boehringer Ingelheim$484
- AstraZeneca$329
- plus $2K from 28 others
What the payments were for
- Food & beverage$7,156100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 78 | $1,287 |
| AbbVie(2 entities) | 66 | $1,195 |
| Pfizer | 49 | $950 |
| Amgen(2 entities) | 33 | $669 |
| Boehringer Ingelheim | 21 | $484 |
| AstraZeneca | 19 | $329 |
| Sanofi-aventis U.S. LLC | 17 | $281 |
| Lilly USA, LLC | 16 | $254 |
| Johnson & Johnson | 10 | $198 |
| Abbott | 7 | $159 |
| Bausch Health US, LLC | 7 | $148 |
| Esperion Therapeutics, Inc. | 7 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $112 |
| Merck | 7 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $88 |
| Novartis | 4 | $85 |
| Biohaven Pharmaceuticals, Inc. | 4 | $77 |
| Astellas Pharma US Inc | 3 | $72 |
| Exact Sciences | 3 | $70 |
| Vanda Pharmaceuticals Inc. | 4 | $68 |
| Amarin Pharma, Inc. | 3 | $66 |
| Myriad Women's Health, Inc. | 1 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $48 |
| Sanofi | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| Mylan Specialty L.p. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $24 |
| GSK | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| IBSA Pharma Inc. | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Antares Pharma, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$7,170 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 38 | $55,197 |
| JardianceEmpagliflozin | 27 | $35,311 |
| OzempicSemaglutide | 31 | $29,978 |
| ViberziEluxadoline | 12 | $19,860 |
| JanuviaSitagliptin Phosphate | 14 | $17,258 |
| WegovySemaglutide | 11 | $14,196 |
| RybelsusSemaglutide | 14 | $14,184 |
| SynthroidLevothyroxine Sodium | 80 | $6,967 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $6,231 |
| TegretolCarbamazepine | 11 | $5,833 |
| Atorvastatin Calcium | 361 | $3,486 |
| Candesartan Cilexetil | 32 | $3,015 |
| Metoprolol Succinate | 111 | $1,745 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 23 | $1,561 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $1,533 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy, Rybelsus | $1,287 | $58,35756 claims |
| PfizerEliquis, Paxlovid | $950 | $56,56555 claims |
| Boehringer IngelheimJardiance | $484 | $35,31127 claims |
| AbbVieViberzi, Synthroid | $1,195 | $26,82892 claims |
| MerckJanuvia | $105 | $17,25814 claims |
| GSKBreo Ellipta | $23 | $6,23112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Fairfax
- Stanley StrickbergerFairfax$93K
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.